Drugs / Karelizumab
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06607770 | Sep 2024 → Aug 2026 overdue | lung cancer | Zhou Chengzhi | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05910177 | Dec 2023 → Aug 2026 overdue | cervical carcinoma | Fujian Cancer Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Karelizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05910177 ↗ |
| Route | Intravenous | “Karelizumab：200 mg，ivgtt” NCT05910177 ↗ |